VW
BIIB icon

Vantage Wealth’s Biogen BIIB Stock Holding History

Vantage Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,549
Closed -$7.53M – 25
2017
Q1 		$7.53M Sell
27,549
-1,280
-4% -$362K 4.11% 17
2016
Q4 		$8.18M Sell
28,829
-312
-1% -$92.5K 4.49% 12
2016
Q3 		$9.12M Buy
29,141
+15
+0.1% +$4.44K 5.2% 4
2016
Q2 		$7.04M Buy
29,126
+7,131
+32% +$1.88M 4.48% 17
2016
Q1 		$5.73M Sell
21,995
-35
-0.2% -$9.24K 3.63% 20
2015
Q4 		$6.75M Buy
22,030
+220
+1% +$63.2K 3.88% 16
2015
Q3 		$6.36M Buy
+21,810
New +$7.2M 3.88% 18

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vantage Wealth's BIIB Position: Q2 2017 in Review

Vantage Wealth sold out of Biogen (BIIB) in Q2 2017, closing a stake of 27,549 shares — an estimated $7.53M sold.

Vantage Wealth first reported a position in BIIB in Q3 2015 and held it in 7 quarters. The position peaked at $9.12M in Q3 2016. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Vantage Wealth reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Vantage Wealth sold 27,549 Biogen shares in Q2 2017, an estimated $7.53M.
  • Vantage Wealth first reported a position in Biogen in Q3 2015 and held it in 7 quarters.
  • Vantage Wealth's Biogen position peaked at $9.12M in Q3 2016.
  • 993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Vantage Wealth's 13F filing for Q2 2017, filed 15 Aug 2017.